Beta Drugs Complete Financial Statements
BETA • Review detailed financials to uncover trends, confirm thesis & journal trades
8 Years of Data
2025 - 2018
Complete Financial Data Export
Export complete financial statements for Beta Drugs (BETA).
Downloads include all available records across all periods.
For market performance, see the
BETA stock price today
.
Profitability Ratios
Net Profit Margin
11.38%
2025 data
EBITDA Margin
21.95%
2025 data
Operating Margin
21.00%
2025 data
Return on Assets
9.63%
2025 data
Return on Equity
21.32%
2025 data
Balance Sheet Ratios
Current Ratio
2.43
2025 data
Debt to Equity
2.21
2025 data
Equity Ratio
45.18%
2025 data
Asset Turnover
0.85
2025 data
Year-over-Year Growth Analysis
Comparing March 2025 vs Period
Revenue Growth
-100.0%
Year-over-Year
Net Profit Growth
-100.0%
Year-over-Year
EBITDA Growth
-100.0%
Year-over-Year
Expense Growth
-100.0%
Year-over-Year
Assets Growth
+71.7%
Year-over-Year
Equity Growth
+25.5%
Year-over-Year
Liabilities Growth
+71.7%
Year-over-Year
Operating Cash Flow Growth
+16.1%
Year-over-Year
Investing Cash Flow Growth
-157.1%
Year-over-Year
Financing Cash Flow Growth
+1575.0%
Year-over-Year
Income Statement
Periods
₹ Crores
| Particulars | None | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 369 | 297 | 228 | 185 | 117 | 91 | 66 | 51 |
| Expenses | 0 | 288 | 236 | 174 | 141 | 91 | 73 | 54 | 41 |
| EBITDA | 0 | 81 | 61 | 54 | 44 | 25 | 18 | 12 | 10 |
| Operating Profit Margin % | 0.00% | 21.00% | 20.00% | 23.00% | 23.00% | 21.00% | 20.00% | 18.00% | 19.00% |
| Depreciation | 0 | 13 | 10 | 10 | 7 | 7 | 4 | 3 | 2 |
| Interest | 0 | 7 | 3 | 2 | 2 | 2 | 3 | 1 | 1 |
| Profit Before Tax | 0 | 57 | 49 | 41 | 34 | 16 | 12 | 8 | 7 |
| Tax | 0 | 15 | 12 | 10 | 10 | 4 | 3 | 0 | 0 |
| Net Profit | 0 | 42 | 36 | 31 | 25 | 12 | 9 | 8 | 7 |
| Earnings Per Share (₹) | 0.00 | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 | 9.79 | 9.30 | 7.82 |
Related Pages for Beta Drugs
Additional stock information and data for BETA
Balance Sheet
Years
Annual Data
₹ Crores
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Total Assets | 436 | 254 | 198 | 158 | 118 | 107 | 83 | 50 |
| Current Assets | 331 | 178 | 128 | 97 | 68 | 56 | 43 | 32 |
| Fixed Assets | 89 | 65 | 63 | 55 | 40 | 44 | 18 | 13 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 3 | 0 | 15 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 347 | 190 | 136 | 103 | 75 | 63 | 50 | 35 |
| LIABILITIES | ||||||||
| Total Liabilities | 436 | 254 | 198 | 158 | 118 | 107 | 83 | 50 |
| Current Liabilities | 136 | 12 | 13 | 17 | 16 | 13 | 9 | 3 |
| Non-Current Liabilities | ||||||||
| SHAREHOLDERS' EQUITY | ||||||||
| Total Equity | 197 | 157 | 123 | 92 | 69 | 57 | 41 | 33 |
| Share Capital | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 |
| Reserves & Surplus | 187 | 148 | 113 | 83 | 59 | 48 | 32 | 24 |
Cash Flow Statement
Periods
₹ Crores
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | 36 | 31 | 23 | 30 | 19 | 8 | 0 | 17 |
| Investing Activities | -36 | -14 | -19 | -22 | -6 | -15 | -21 | -11 |
| Financing Activities | 118 | -8 | -3 | -1 | -8 | 9 | 12 | 5 |
| Net Cash Flow | 118 | 10 | 2 | 7 | 5 | 2 | -9 | 12 |